Fairmount Funds Management LLC → Dianthus Therapeutics, Inc. /DE/ DNTH

Item 4 of the Statement is hereby amended and supplemented as follows: Fund II purchased the shares of Common Stock referenced in Item 3 for investment purposes. On March 4, 2025, Mr. Kiselak resigned from the Board of Directors of the Company. Mr. Kiselak's resignation was not the result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices. As a result of his resignation, Mr. Kiselak no longer may be deemed to have influence over the corporate activities of the Company, including activities which may relate to items described in subparagraphs (a) through (j) of Item 4 of Schedule 13D. The Reporting Persons do not have any present plans or proposals that relate to or would result in any of the actions described in subparagraphs (a) through (j) of Item 4 of Schedule 13D, although, the Reporting Persons, at any time and from time to time, may review, reconsider and change their position and/or change their purpose and/or develop such plans and may seek to influence management or the board of directors of the Company with respect to the business and affairs of the Company and may from time to time consider pursuing or proposing such matters with advisors, the Company or other persons.